These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19686353)

  • 1. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
    Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting - A systematic review and meta-analysis.
    Raghunath A; Chandrasekara SD; Anthony SN; Markman B
    Crit Rev Oncol Hematol; 2020 Aug; 152():103012. PubMed ID: 32593142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone exacerbates cytotoxic chemotherapy induced lethargy and weight loss in female tumor free mice.
    Wong J; Tran LT; Lynch KA; Wood LJ
    Cancer Biol Ther; 2018 Jan; 19(1):87-96. PubMed ID: 29231783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron induced blindness: a pharmacovigilance database study.
    Barus R; Potey C; Gautier S; Wabont G
    Expert Opin Drug Saf; 2024 Aug; 23(8):1017-1020. PubMed ID: 37852931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vomiting after intrathecal chemotherapy under anesthesia in pediatric patients with hematologic cancers: A cohort study.
    França de Moraes GH; Lima LC; Couceiro TCM; Lins MM; Cumino DO; Simões LABM; Mello MJG
    Paediatr Anaesth; 2024 Jan; 34(1):51-59. PubMed ID: 37727104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.
    Janowitz T; Kleeman S; Vonderheide RH
    Oncologist; 2021 Apr; 26(4):269-273. PubMed ID: 33465258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study.
    Tsutsumi T; Imai S; Momo K; Kashiwagi H; Sato Y; Sugawara M; Takekuma Y
    Int J Clin Pharm; 2024 Apr; 46(2):421-428. PubMed ID: 38158470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal and Neuropsychological Symptoms Are Associated With Distinct Vomiting Profiles in Patients Receiving Chemotherapy.
    Singh KP; Cooper BA; Paul SM; Ruddy K; Singh AB; Chen J; Pituch KA; Grys TE; Singh P; Batalini F; Hammer MJ; Levine JD; Miaskowski C
    Oncol Nurs Forum; 2024 Jun; 51(4):361-380. PubMed ID: 38950093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.
    Rock EM; Limebeer CL; Parker LA
    Exp Brain Res; 2014 Aug; 232(8):2511-34. PubMed ID: 24792499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral ondansetron for preventing nausea and vomiting.
    Cooke CE; Mehra IV
    Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.